Prihlásiť sa Zaregistrujte sa zadarmo

Hrubá marža spoločnosti Abeona Therapeutics Inc

Aká je hodnota metriky Hrubá marža spoločnosti Abeona Therapeutics Inc?

Hodnota metriky Hrubá marža spoločnosti Abeona Therapeutics Inc je 100.00%

Aká je definícia metriky Hrubá marža?



Hrubá marža (Gross margin) je rozdiel medzi príjmami a nákladmi na predaný tovar vydelený príjmami a vyjadrený v percentách.

Gross margin is a type of profit margin, specifically a form of profit divided by net revenue. It is generally calculated as the selling price of an item, minus the cost of goods sold (production or acquisition costs, not including indirect fixed costs like rent, or administrative costs). The purpose of margins is to give a description of the gross profit.

Hrubá marža spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Abeona Therapeutics Inc

Čomu sa venuje spoločnosť Abeona Therapeutics Inc?

abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t

Firmy s metrikou hrubá marža podobnou spoločnosti Abeona Therapeutics Inc